Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-up
Authors
Abreu, D. R.Reck, M.
Sendur, N.
Park, K.
Lee, D. H.
Cicin, I.
Yumuk, P. F.
Orlandi, F. J.
Leal, T. A.
Soparattanapaisarn, N.
Langleben, A.
Califano, Raffaele
Medgyasszay, B.
Hsia, T. C.
Otterson, G. A.
Woods, T.
Jensen, E.
Samkari, A.
Boyer, M.
Issue Date
2022
Metadata
Show full item recordCitation
Abreu DR, Reck M, Sendur N, Park K, Lee DH, Cicin I, et al. Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-up. Annals of Oncology. 2022;33:S30-S1.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.02.015Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.02.015Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.02.015